Beacon Therapeutics Treats First Patient in New Gene Therapy Trial for X-Linked Retinitis Pigmentosa

Progress in gene therapy for inherited retinal diseases continues to build momentum. This week, Beacon Therapeutics announced that the first patient has been treated in its LANDSCAPE clinical trial , a new study evaluating bilateral dosing of an investigational gene therapy for X-linked retinitis pigmentosa (XLRP) — one of the most severe forms of RP. While this trial is not specific to Bardet-Biedl Syndrome (BBS), it represents another meaningful step forward for the broader retinal gene therapy field — and reinforces the pace at which vision-saving science is advancing. What Is the LANDSCAPE Trial? The LANDSCAPE trial is an open-label clinical study designed to evaluate the safety of administering gene therapy to both eyes in people with XLRP. Most early retinal gene therapy trials treat only one eye at a time, so studying bilateral dosing is an important milestone. Key details of the study include: Evaluation of laru-zova , an investigational gene therapy Subretinal delivery to both eyes Enrollment of males ages 12–50 with confirmed XLRP Trial sites across the United States Focus